Press Releases from XL-protein GmbH (6 total)
XL-protein and Antlia Bioscience Announce Collaboration to Develop Long-acting P …
SAN DIEGO, U.S.A., and FREISING, Germany, 15th October, 2020: Antlia Bioscience, Inc., a privately owned biopharmaceutical company located in San Diego, California, and XL-protein GmbH, a privately owned biopharmaceutical company located in Germany, are pleased to announce a Strategic Alliance using XL-protein’s proprietary PASylation® technology for plasma half-life extension to develop a novel, long-acting, peptide therapeutic treatment for chronic heart failure. Brian Johnson, Antlia Bioscience’s CEO commented, “chronic heart failure…
XL-protein and DNX Biopharmaceuticals Announce Collaboration to Develop Novel In …
Freising, Germany and San Diego, CA, February 25, 2020 -- XL-protein has extended its existing partnership with DNX Biopharmaceuticals, a biopharmaceutical company developing nonimmunogenic, long-acting therapeutic proteins for the treatment of patients with life-long diseases, to develop novel inflammasome-directed therapeutics for the treatment of diseases linked to inflammation, autoinflammation and oncology. DNX has exercised an option for an exclusive license to research, develop and commercialize a novel antagonist from within…
DNX and XL-protein Announce Collaboration to Develop Novel, Long-Acting Biopharm …
New Half-Life Extension Platform Technology Will Support the Development and Commercialization of Novel Therapeutic Proteins Addressing Unmet Needs in Immunology, Metabolism and Ophthalmology
Irvine, CA and Freising, Germany, June 30, 2015 — DNX Biopharmaceuticals, Inc. (“DNX”) a company with a team of experienced industry professionals with a long and successful track record of developing and manufacturing biopharmaceutical products, and XL-protein GmbH (“XLp”), a leader in protein engineering and modification technologies, today…
YEDA and XL-protein sign business collaboration agreement to commercialize PASyl …
FREISING, GERMANY & REHOVOT, ISRAEL, October 21, 2014:
Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science, Israel, and XL-protein GmbH, Germany, a privately owned biopharmaceutical company, have signed a business collaboration agreement to commercialize a PASylated interferon superagonist – PAS-YNSa8 – which has been jointly developed by scientists at the Weizmann Institute and XL-protein. Under this agreement, YEDA acquires the worldwide exclusive rights…
XL-protein announces publication of key scientific data on its PASylation techno …
FREISING, GERMANY, August 30, 2013 – XL-protein GmbH announced today that key scientific data have been published in the journal Protein Engineering, Design & Selection (2013, Vol. 26, No. 8, pp. 489–501, 2013). The Open Access Publication "PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins" is also available for download at XL-protein's web site (http://www.xl-protein.com/publications.html).
A major limitation of biopharmaceutical proteins is their fast…
XL-protein announces preclinical in vitro and in vivo data for its PASylated hum …
FREISING, GERMANY, September 23, 2011 – XL-protein GmbH, a German biotech company specialised in the development of biopharmaceuticals with extended plasma half-life, announced today preclinical in vitro and in vivo data for its xl020 PAS-hGH program. The xl020 data demonstrate XL-protein's ability to furnish an approved biological drug with improved in vivo stability and plasma half-life using its proprietary PASylation® technology, leading to enhanced efficacy in an established animal model.
The…
